ZSAN - Zosano Pharma Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.6300
0.0000 (0.00%)
As of 12:52PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.6300
Open3.5700
Bid3.63 x 1000
Ask3.69 x 4000
Day's Range3.5700 - 3.7600
52 Week Range3.2900 - 25.7000
Volume4,873
Avg. Volume91,976
Market Cap43.462M
Beta (3Y Monthly)3.31
PE Ratio (TTM)N/A
EPS (TTM)-4.71
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed brand name Qtrypta™ for M207, the Company’s investigational drug for treatment of migraine.  A request for proprietary name review and final approval for Qtrypta will be included when Zosano submits a New Drug Application (NDA) for M207. The name Qtrypta (pronounced "kew-trip-tah") was developed in compliance with the FDA's Guidance for Industry, Contents of a Complete Submission for the Evaluation of Proprietary Names.  The proprietary name development program  included research with physicians and pharmacists, and FDA’s  conditional approval validated Qtrypta is a proprietary name that is consistent with the FDA's goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use.  Final approval of the Qtrypta brand name is conditional on FDA approval of the product candidate, M207.

  • GlobeNewswirelast month

    Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update

    Selected a contract manufacturer for commercial launch of M207Completed first required data set in long-term safety study of M207Appointed Greg Kitchener as Chief Financial.

  • GlobeNewswirelast month

    Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast to be held on Wednesday, November 14, 2018 at 4:30PM ET. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Stellus Capital Investment, Nuance Communications, ProPetro Holding, Sanchez Energy, Granite Point Mortgage Trust, and Zosano Pharma Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study  

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that more than 150 evaluable subjects have completed their six month visit in the M207-ADAM study (the "Study"), a long-term, open-label safety study for the acute treatment of migraine. No unexpected safety signals have been identified during the first six months of the trial and there have been no study drug related serious adverse events. The total number of investigator reported adverse events, with 4,000 applications to date, is 625 of which 232 are reported as skin site reactions and 120 triptan related adverse events.

  • GlobeNewswire2 months ago

    Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System (“ADAM™”), today announced that it will host a Key Opinion Leader (KOL) meeting focusing on new treatments for migraine and the migraine patients’ perspective on Wednesday, October 24th, in New York City. The meeting will feature presentations by KOLs Stewart J. Tepper, M.D. (Dartmouth-Hitchcock Medical Center) and Lawrence C. Newman, M.D. (NYU Langone) who will discuss updates on newly emerging treatments for the prevention of migraine, including CGRP antibodies, neurostimulation devices and new acute drug treatment products.

  • GlobeNewswire2 months ago

    Zosano Appoints New Chief Financial Officer

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System (“ADAM™”), today announced the appointment of Greg Kitchener to the position of chief financial officer (CFO). “We are pleased to announce the addition of Greg Kitchener to Zosano as our new CFO,” said John Walker, chief executive officer and chairman of the board at Zosano. “Greg joins us at a pivotal time in the advancement of our clinical pipeline.

  • GlobeNewswire2 months ago

    Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System (“ADAM™”), today announced a manufacturing and supply agreement for M207 with a leading global contract development and manufacturing organization, which serves more than 400 clients in the pharmaceutical and biotechnology sectors. Under the terms of the agreement, Zosano will transfer its proprietary technology for the coating of zolmitriptan onto the ADAM delivery system. Additionally Zosano has entered into a long-term manufacturing and supply agreement.

  • GlobeNewswire3 months ago

    Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System (“ADAM™”), announced today that it has entered into a new capital equipment leasing line of up to $14.0 million from Trinity Capital Investment (“Trinity”), a leading venture debt provider. This process will be capable of producing as many as 1.5 million doses per year, which is the Company’s target at launch.

  • GlobeNewswire3 months ago

    Zosano Pharma Completes Manufacture of M207 Registration Batches

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microneedle (“ADAM™”) technology, today announced the release of three registration batches of M207, the Company’s lead development candidate. The registration batches will be used to support Zosano’s New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA). Twelve months of room temperature stability for a product candidate are typically required in order for the FDA to assess manufacturability and stability of a drug product.

  • Shareholders Should Check If Insiders Own Shares In Zosano Pharma Corporation (NASDAQ:ZSAN)
    Simply Wall St.3 months ago

    Shareholders Should Check If Insiders Own Shares In Zosano Pharma Corporation (NASDAQ:ZSAN)

    Every investor in Zosano Pharma Corporation (NASDAQ:ZSAN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to seeRead More...

  • ACCESSWIRE4 months ago

    Zosano Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Zosano Pharma Corp. (NASDAQ: ZSAN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern Time. ...

  • ACCESSWIRE5 months ago

    Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks

    For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.

  • Zosano Pharma’s Positive Non-Clinical Trial Results
    Market Realist5 months ago

    Zosano Pharma’s Positive Non-Clinical Trial Results

    Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday. $4.14 represented ~15% growth from the stock’s 52-week low of $3.61 on February 13. Zosano Pharma hit a 52-week high of $27.8 on July 18, 2017.

  • ACCESSWIRE5 months ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • Zosano Pharma (ZSAN) Stock Can Reach $19 in the Next 12 Months, Says BTIG
    SmarterAnalyst6 months ago

    Zosano Pharma (ZSAN) Stock Can Reach $19 in the Next 12 Months, Says BTIG

    Yes, you're reading this right. BTIG analyst Robert Hazlett is expecting Zosano Pharma (NASDAQ:ZSAN) shares to reach $19.00 in the next 12 months, which implies an upside of 400% from current levels. In a very upbeat and promising report, Hazlett explains why he is initiating coverage on ZSAN with a Buy rating: "We believe M&A potential exists with Zosano [...] Since Zosano is effectively a one product company with a modest infrastructure, there is a reasonable chance that a larger industry suitor could emerge and take over the company’s operations. The analyst continued, "We assess the total value of M207 at $16.21 per ZSAN share, assuming Zosano continues to operate independently.

  • ACCESSWIRE7 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.